Incident venous thromboembolism in biopsy-proven metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study
Journal of Thrombosis and Haemostasis · 2026-08 · 24 (8) · 2910-2922
DOI: 10.1016/j.jtha.2026.04.019 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-08. Verfasst von Shuai Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Pennsylvania, USA; Unit of Cardiovascular and Nutritional Epide…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Fatty Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association, VIVA Foundation for Children with Cancer.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
BACKGROUND: The absolute and relative risk of venous thromboembolism (VTE) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely unexplored. We conducted a nationwide cohort study to explore this. OBJECTIVES: To calculate risk of developing VTE among MASLD. METHODS: This nationwide, population-based matched cohort study in Sweden included all individuals with biopsy-confirmed MASLD (1965-2017). MASLD was histologically classified into simple steatosis, metabolic dysfunction-associated steatohepatitis, noncirrhotic fibrosis, and cirrhosis. Each MASLD case was matched to up to 5 general population comparators. VTE events were identified using the Swedish National Patient Register up until 2021. RESULTS: We included 11 073 individuals with MASLD and 50 078 comparators. During a median follow-up of 18.6 years, incident VTE occurred in 1291 patients with MASLD and 4067 comparators. The incidence rate of VTE was higher in MASLD (7.6 vs 3.4 per 1000 person-years [PYs]), yielding an adjusted hazard ratio (aHR) of 1.78 (95% CI, 1.65-1.91). The absolute risk difference was 3.9 per 1000 PYs, equating to 1 extra VTE per 26 patients with MASLD over 10 years. MASLD was associated with a higher incidence of VTE triggered by cancer, hospitalization, and surgery. Higher aHRs were observed in women compared with men, and in patients with baseline cancer or metabolic disorders compared with those without. The risk of portal vein thrombosis was markedly elevated (aHR, 3.40; 95% CI, 2.93-3.95), increasing progressively with MASLD severity (P = .003). Findings were similar when siblings were used as comparators to account for intrafamilial confounding. CONCLUSION: Biopsy-confirmed MASLD was associated with a higher incidence of VTE, particularly portal vein thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Pennsylvania, USA; Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, S…
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology and Hepatology, University Digestive Health Care Center Basel - Clarunis, Switzerland.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Centre for Digestive Health, Gastroenterology Unit, Department of Gastroenterology, Dermatovenereology and Rheumatology, Ka…
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Center for Primary Health Care Research, Department of Clinical Sciences, Lund University and Region Skåne, Malmö, Sweden.
- Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Förderung
- American Heart Association
- VIVA Foundation for Children with Cancer
Zitieren
APA
Yuan, S., Ebrahimi, F., Forss, A., Sun, J., Zöller, B., Hagström, H., & Ludvigsson, J. F. (2026). Incident venous thromboembolism in biopsy-proven metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study. Journal of Thrombosis and Haemostasis, 24(8), 2910-2922. https://doi.org/10.1016/j.jtha.2026.04.019
Vancouver
Yuan S, Ebrahimi F, Forss A, Sun J, Zöller B, Hagström H, et al. Incident venous thromboembolism in biopsy-proven metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study. Journal of Thrombosis and Haemostasis. 2026;24(8):2910-2922. doi:10.1016/j.jtha.2026.04.019
BibTeX
@article{Yuan2026,
author = {Yuan, Shuai and Ebrahimi, Fahim and Forss, Anders and Sun, Jiangwei and Zöller, Bengt and Hagström, Hannes and Ludvigsson, Jonas F},
title = {Incident venous thromboembolism in biopsy-proven metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {8},
pages = {2910--2922},
doi = {10.1016/j.jtha.2026.04.019}
}
EUVIMED